Replies to post #97214 on Biotech Values

[DewDiligence]

Good catch, ghmm! This is a notable trial design insofar as BI is sticking with ribavirin in all trial arms. I presume BI has replicon data showing that the BI 207127 + BI 201335 combination is strongly boosted by ribavirin.

The clinicaltrials.gov entry says, “Study First Received: May 3, 2010,” which explains why BI’s program is not included in #msg-51233708.

[DewDiligence]

Clinical Trials of BI’s HCV Non-Nuke, BI 207127

Phase-1 with SoC (54 patients, estimated completion Mar 2011):
http://clinicaltrials.gov/ct2/show/NCT00905632

Phase-1 all-oral with BI 201335 protease inhibitor and ribavirin (302 patients, estimated completion Jun 2014):
http://clinicaltrials.gov/ct2/show/study/NCT01132313

These trials are effectively phase-2’s in size and scope; I think Boehringer Ingelheim has designated them as phase-1’s because, as a private company, it is incentivized to play down the progress of the program.